Webinar – In Vitro Approaches to Cosmetic Safety Assessment

In April, our Head of Toxicology, Dr Paul Walker joined speakers from Unilever, Proctor and Gamble, Humane Society International and Lhasa for a free webinar entitled ‘The Use of New Approach Methodologies for Cosmetic Safety Assessment without Animal Testing’, presenting a segment entitled ‘In Vitro Approaches to Cosmetic Safety Assessment’.  The webinar was hosted by American Society for Cellular and Computational Toxicology (ASCCT) and European Society of Toxicology In Vitro (ESTIV).

New legislation and an increasing global desire to perform chemical safety assessments without animal testing is driving a wave of innovative approaches to chemical safety testing not yet represented by official regulatory guidance.

The webinar details the Next Generation Risk Assessment (NGRA) approach to cosmetic safety assessment and covers several topics based on the principals outlined by the International Co-operation on Cosmetics Regulation (ICCR) and Safety Evaluation Ultimately Replacing Animal Testing (SEURAT) workflows.  This includes exposure-based safety assessment of cosmetics, the application of in silico models, in vitro approaches and integration of new approaches used in the decision-making process for cosmetic safety processes.

Dr Walker presents a portion of the webinar which describes Cyprotex’s work in the field of in vitro approaches to cosmetic and ingredients safety assessment, including High Content Imaging (HCI) in 2D and 3D cellular models, and an overview of a next generation risk assessment cell stress panel that has been developed.  This panel, in combination with other cellular assays and in silico approaches could provide a powerful decision-making tool with regards to non-animal safety assessments.

The webinar is free to view online by clicking here.

For further information on the topic presented by Dr Walker, contact us at enquiries@cyprotex.com

This website is intended to assist industry participants, customers and employees to understand Cyprotex's global operations and ambitions.